Patients receiving clozapine (Clozaril, FazaClo, Versacloz) or a long-acting injectable antipsychotic experienced no worsening of symptoms or side effects when switched to monotherapy.

Patients who switched to oral, nonclozapine antipsychotic (NCAP) experienced reduced side effects but also increased symptoms.

Why this matters

Chronically ill patients may face some symptom risks when switching from polypharmacy to monotherapy, but benefits are also possible.

In chronically ill patients switching to monotherapy, clozapine or an injectable antipsychotic may be the best choice.

Study design

Patients with schizophrenia or schizoaffective disorder earlier treated with oral NCAP (n=45) or clozapine/injectable antipsychotics (C/IAP; n=45) were switched to monotherapy (n=43) or continued with polypharmacy (n=47).

We use cookies in order to provide you with a user-friendly and effective service as well as content adapted to your interests. We also use cookies to dynamically display Univadis ads and ads from our business partners on both Univadis and selected third party websites. To learn more about the cookies on this site, including how to manage them, click here.

Univadis will update its Terms of Use and Privacy Policy on January 12, 2016. Please contact privacy@aptushealth.com if you have any questions about these changes. If you continue to use Univadis after January 12, 2016 the new Terms of Use and Privacy Policy will apply. By your continued use of Univadis, you accept and agree to these terms and policies.